Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Guided Posters

Adrenal and Neuroendocrine - Clinical (1)

ea0063gp223 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Small molecule allosteric agonist of relaxin receptor ML290 demonstrates antifibrotic properties in liver fibrosis

Kaftanovskaya Elena , Ng Hooi Hooi , Soula Mariluz , Rivas Bryan , Myhr Courtney , Ho Brian , Cervantes Briana , Bishop Colin , Shupe Thomas , Wilson Kenneth , Barnaeva Elena , Ferrer Marc , Southall Noel , Marugan Juan , Agoulnik Irina , Agoulnik Alexander

The beneficial effects of relaxin peptide treatment have been demonstrated in animal models of liver fibrosis. However, the low stability of peptide in vivo prevents using it in chronic treatments. We have identified a series of small molecule allosteric agonists of the human relaxin receptor, RXFP1. The therapeutic effects of lead compound ML290 was tested in various models of liver fibrosis. To analyze the anti-fibrotic effects of ML290 on gene expression, we used p...

ea0063gp224 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Caffeine upregulates hepatic SHBG production by increasing adiponectin in white adipose tissue

Brianso-Llort Laura , Fuertes-Rioja Lidia , Perez Lorena Ramos , Hernandez Cristina , Simo Rafael , Selva David

Epidemiological studies have shown that caffeine increases plasma SHBG levels and also reduce the risk of type 2 diabetes. There are no reports describing any molecular mechanism by which caffeine regulates hepatic SHBG production. The aim of the present study was to explore whether caffeine regulates SHBG production and to determine the associated molecular mechanisms. For this purpose, in vitro and in vivo studies were performed using human HepG2 cells and ...

ea0063gp225 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Activation of the ATM/Akt/CREB/eNOS expression signaling axis by aphidicolin increases nitric oxide production to attenuate endothelial cell death

Cho Du-Hyong , Park Jung-Hyun , Lee Jee Young , Lee Hyeon-Ju , Jo Inho

Previously, we reported that aphidicolin acutely increases nitric oxide (NO) production in bovine aortic endothelial cells (BAECs) by increasing phosphorylation of endothelial nitric oxide synthase at serine 1179 (p-eNOS-Ser1179) and decreasing phosphorylation at serine 116 (p-eNOS-Ser116) without altering eNOS protein expression. Here, we demonstrate that prolonged treatment with aphidicolin (over 24 h) also increased NO production in BAECs. Unlike the a...

ea0063gp226 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Evaluation of the CCK-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma – final Results of the phase 0 ‘Lumed’ Study

Rottenburger Christof , Nicolas Guillaume , McDougall Lisa , Kaul Felix , Cachovan Michael , Schibli Roger , Geistlich Susanne , Behe Martin , Wild Damian , Christ Emanuel

Objectives: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). As MTC expresses cholecystokinine-2 (CCK-2) receptors at a high incidence and density, targeting the CCK-2 receptor with radiolabelled gastrin analogues is a potential approach for radionuclide therapy. Unfortunately, kidney and bone marrow toxicity precluded therapeutic applications of CCK-2 re...

ea0063gp227 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Multikinase inhibitors for the treatment of progressive, metastatic parathyroid cancer

Krupinova Julia , Mokrysheva Natalia , Pigarova Ekaterina , Gorbunova Vera , Voronkova Iya , Rozhinskaya Liudmila

Introduction: The treatment of choice for parathyroid carcinoma (PC) is a radical en bloc resection. Treatment options for patients with metastatic PC are limited especially if a complete tumor removal cannot be performed. We present four cases of PC patients with multiple metastasis and refractory hypercalcemia that eventually received a multikinase inhibitor with different response on therapy.Clinical cases: The first patient was a 27-year-old woman wi...

ea0063gp228 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Serine-threonine PAK1 as a novel common node for estrogen- and prolactin-dependent pathways in breast cancer

Diakonova Maria

Even though serine-threonine kinase PAK1 is activated by estrogen and plays an important role in breast cancer, the role of PAK1 in estrogen response is not fully understood. We have shown that estrogen activates PAK1 through both ERĪ± and GPER1 plasma membrane receptors and that cytoplasmic Etk/Bmx directly phosphorylates Tyr153-PAK1 and activates PAK1 in response to estrogen. We have described a signaling complex composed of pTyr-PAK1, Etk, the heterotrimeric G-protein s...

ea0063gp229 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Melatonin prevented beta cell senescence against glucolipotoxicity

Kim Mi-kyung , Jung Hye Sook , Jang Jeong Eun , Kim Tae Nyun , Kwon Min Jeong , Lee Soon Hee , Rhee Byung Doo , Park Jeong Hyun

Beta cell senescence is being regarded as the one of the mechanisms of beta cell dysfunction. Melatonin secreted primarily from the pineal glandregulates a variety of physiological functions, such as sleep, circadian rhythms, and neuroendocrine actions. Melatonin has also very strong anti-oxidant effects. The effects of melatonin on the pancreatic beta cell senescence induced by glucolipotoxicity have not been studied. INS-1 cells were exposed to 33mM glucose with palmitate 20...

ea0063gp230 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Low-dose pollutant mixture triggers metabolic disturbances in ovariectomized mice and comparison with the effects of 17β-estradiol (E2) treatment

Julien Benoit , Vega Nathalie , Pinteur Claudie , Vidal Hubert , Naville Danielle , Le Magueresse-Battistoni Brigitte

Introduction: Environmental pollutants especially those endowed with endocrine disrupting activities have been shown to contribute to metabolic related diseases suggesting that hormonal deficit conditions as observed in post-menopausal women may constitute aggravating conditions. To explore this hypothesis, we used the model developed in the laboratory which consists in a chronically exposure of mice to low-dosed chemicals in mixture incorporated in a high-fat-high-sucrose die...

ea0063gp231 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

In vitro effects of bisphenol A and its analogs on human melanocortin 4 receptor

Louvigne Mathilde , Gourdin Louis , Briet Claire , Rodien Patrice , Munier Mathilde

Bisphenol A (BPA) is a widely used chemical and belongs to the list of metabolism-disrupting chemicals. BPA is banned in several countries and replaced by others BPA-analogs. We investigate the effects of BPA and 6 BPA-analogs (BPS, BPAF, BPF, BPB and BADGE) on the response of the human melanocortin 4 receptor (MC4R), a receptor involved in food intake and weight control, to its natural ligands. We used HEK293 cells line transiently transfected with human MC4R to determine the...

ea0063gp232 | Adrenal and Neuroendocrine - Clinical (1) | ECE2019

Can phthalates impair liver function?

Medic-Stojanoska Milica , Milosevic Natasa , Milanovic Maja , Stojanoski Stefan , Vukovic Bojan , Icin Tijana , Bajkin Ivana , Stepanovic Kristina , Sudji Jan , Milic Natasa

Introduction: The impairment of liver function and enhancement for NAFLD development may be attributed to the ubiquitous exposure to endocrine disrupting chemicals such as phthalates. In this study the urinary levels of monoethyl phthalate (MEP) and mono-(2-ethylhexyl) phthalate (MEHP) were compared with the parameters of hepatic function and lipids in overweight, diabetic patients and normal weight population.Methods and patients: In 305 volunteers of b...